Cargando…

How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review

INTRODUCTION: The introduction of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) over the last two decades has prompted the economic assessments of these treatments by reimbursement authorities. The aim of this systematic literature review was to evaluate the modeling appr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiyani, Anggie, Badgujar, Lohit, Khurana, Vivek, Adlard, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571458/ https://www.ncbi.nlm.nih.gov/pubmed/34279847 http://dx.doi.org/10.1007/s40120-021-00264-1

Ejemplares similares

Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
por: Huisman, Eline, et al.
Publicado: (2017)

Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil
por: Vasanthaprasad, Vijayalakshmi, et al.
Publicado: (2022)

How Have Cancer Clinical Trial Eligibility Criteria Evolved Over Time?
por: Yaman, Anil, et al.
Publicado: (2016)

How Could Language Have Evolved?
por: Bolhuis, Johan J., et al.
Publicado: (2014)

Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review
por: Jain, Paridhi, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)

How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?
por: Braune, Stefan, et al.
Publicado: (2022)

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
por: Bhan, Virender, et al.
Publicado: (2023)

Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies
por: Regnault, Antoine, et al.
Publicado: (2023)

Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis
por: Samjoo, Imtiaz A, et al.
Publicado: (2023)

How to run a multiple sclerosis relapse clinic
por: Tallantyre, Emma C, et al.
Publicado: (2016)

Attitudes and Arguments in the Voluntary Assisted Dying Debate in Australia: What Are They and How Have They Evolved Over Time?
por: Kresin, Tracee, et al.
Publicado: (2021)

Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer
por: Nayan, Madhur, et al.
Publicado: (2018)

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany
por: Koeditz, Dominik, et al.
Publicado: (2022)

The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care
por: Asano, Miho, et al.
Publicado: (2015)

Metals and Alzheimer’s Disease: How Far Have We Come in the Clinic?
por: Adlard, Paul A., et al.
Publicado: (2018)

The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
por: Perrone, Valentina, et al.
Publicado: (2022)

Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges
por: Badgujar, Kirtikumar C., et al.
Publicado: (2020)

Individual Differences in the Patient Experience of Relapsing Multiple Sclerosis (RMS): A Multi-Country Qualitative Exploration of Drivers of Treatment Preferences Among People Living with RMS
por: Tatlock, Sophi, et al.
Publicado: (2023)

The Evolving Economics of Implementation
por: Knocke, Kathleen, et al.
Publicado: (2022)

Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
por: Aungsumart, Saharat, et al.
Publicado: (2023)

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
por: Cutter, Gary R., et al.
Publicado: (2016)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Evolving Landscape of Multiple Sclerosis in India: Challenges in the Management
por: Kumar, Sudhir, et al.
Publicado: (2018)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Seasonal variation in multiple sclerosis relapse
por: Harding, Katharine, et al.
Publicado: (2017)

Factors Involved in Relapse of Multiple Sclerosis
por: Kamel, Fatemah Omar
Publicado: (2019)

Osteopontin Is Associated with Multiple Sclerosis Relapses
por: Stampanoni Bassi, Mario, et al.
Publicado: (2023)

In and Out of Consciousness: How Does Conscious Processing (D)evolve Over Time?
por: Aru, Jaan, et al.
Publicado: (2017)

How will our understanding of human development evolve over the next 10 years
por: Brivanlou, Ali H., et al.
Publicado: (2021)

Clinical Pharmacy Activities in Swiss Hospitals: How Have They Evolved from 2013 to 2017?
por: Studer, Helene, et al.
Publicado: (2020)

Understanding how stress responses and stress-related behaviors have evolved in zebrafish and mammals
por: de Abreu, Murilo S., et al.
Publicado: (2021)

The effect of prioritization over cognitive-motor interference in people with relapsing-remitting multiple sclerosis and healthy controls
por: Postigo-Alonso, Barbara, et al.
Publicado: (2019)

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
por: Singer, Barry A, et al.
Publicado: (2023)

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis
por: Nicholas, Jacqueline, et al.
Publicado: (2020)

Have plants evolved to self-immolate?
por: Bowman, David M. J. S., et al.
Publicado: (2014)

The Evolvement of OCT and OCT-A in Identifying Multiple Sclerosis Biomarkers
por: Donica, Vlad Constantin, et al.
Publicado: (2023)

How digital marketing evolved over time: A bibliometric analysis on scopus database
por: Faruk, Mohammad, et al.
Publicado: (2021)

Migration and mental health over the past 20 years: how has the situation evolved?
por: Duveau, C, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ikjso3sgf5n9lkcf5n5s8luifa